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Abstract: In recent years, the incidence of both liver and biliary tract cancer has increased.
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are the two most common types of
hepatic malignancies. Whereas HCC is the fifth most common malignant tumor in Western countries,
the prevalence of CCA has taken an alarming increase from 0.3 to 2.1 cases per 100,000 people. The lack
of specific biomarkers makes diagnosis very difficult in the early stages of this fatal cancer. Thus,
the prognosis of CCA is dismal and surgery is the only effective treatment, whilst recurrence after
resection is common. Even though chemotherapy and radiotherapy may prolong survival in patients
with CCA, the 5-year survival rate is still very low—a significant global problem in clinical diagnosis
and therapy. The mitogen-activated protein kinase (MAPK) pathway plays an important role in signal
transduction by converting extracellular stimuli into a wide range of cellular responses including
inflammatory response, stress response, differentiation, survival, and tumorigenesis. Dysregulation
of the MAPK cascade involves key signaling components and phosphorylation events that play an
important role in tumorigenesis. In this review, we discuss the pathophysiological role of MAPK,
current therapeutic options, and the current situation of MAPK-targeted therapies in CCA.
Keywords: cholangiocarcinoma (CCA); mitogen-activated protein kinases (MAPK); cholangiocytes;
hepatocytes; epithelial to mesenchymal transition (EMT); cancer-associated fibroblasts (CAFs)
1. Introduction
Cholangiocarcinoma (CCA)
Cholangiocarcinoma (CCA) is a malignant adenocarcinoma characterized by biliary tract
differentiation and is the second most common primary liver tumor. Although CCA in most countries
is considered a rare form of cancer with an incidence rate of <6 cases per 100,000 of the population [1–3],
the global incidence of CCA (1/100,000) is steadily on the rise, reaching up to 2.1/100,000 in Western
countries, and having increased almost 165% in the United States over the last 30 years period [4–7].
Risk factors for CCA include chronic viral hepatitis (types B and C), liver cirrhosis, biliary stone disease,
chronic infections (infection with Clonorchis sinensis, Opisthorchis viverrini, and Opisthorchis felineus
species in Southeast Asia), metabolic syndrome, obesity, and toxic substances (e.g., tobacco and alcohol).
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In addition, other factors such as parasitic infections, hepatolithiasis, Caroli’s disease, and primary
sclerosing cholangitis (PSC) are identified risk factors [8]. Although hepatolithiasis is more commonly
found in Asia, it has also been associated with CCA in Western populations [9,10]. In addition,
CCA development has also been linked to genetic variants such as DNA repair, inflammation, and
carcinogen metabolism [3].
Depending on the anatomical location, CCA can be basically divided into three categories:
intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) [5,11]. The above-mentioned elevation in
global CCA incidence is mainly due to the increase in iCCA cases [12]. It is noteworthy that although
these three subtypes share common features, they also have important inter- and intra-tumoral
differences that may affect the pathogenesis and outcome of the disease [13–16]. According to a recent
study, by using integrated molecular analysis research methods, CCA can be divided into two categories:
inflammatory or proliferative. The former is characterized by the activation of inflammatory signaling
pathways, overexpression of cytokines, and the activation of the signal transducer and activator of
the transcription 3 (STAT3) pathway, which is characterized by the activation of oncogenic signaling
pathways including RAS, mitogen-activated protein kinases (MAPKs), and epithelial to mesenchymal
transition (EMT) [17]. Consequently, a number of important signaling pathways involved in CCA have
been discovered including RAF/mitogen-activated protein kinase (MEK)/MAPK, transforming growth
factor-β (TGF-β)/SMADs, phosphatidylinositol 3-kinase (PI3K)/AKT, WNT, interleukin-6 (IL-6)/STAT-3,
and NOTCH [18,19]. The MAPKs not only play an important role in the initiation and formation of
CCA, but are also closely linked to many CCA-related signaling pathways, as above-mentioned.
2. The MAPK Signaling Pathways: ERK1/2, JNK-1/2/3, and p38
There are at least three different MAPK signal transduction pathways that modulate and transduce
extracellular signals into the nucleus to induce response genes in mammalian cells including ERK1/2,
c-Jun NH2-terminal kinase(JNK)1/2/3, and p38 [20,21]. The ERK kinase family is composed of ERK1
(p44) and ERK2 (p42). The JNK kinase family is composed of JNK1, JNK2, and JNK3. Finally, the p38
MAPKs family can be further divided into two subgroups, p38α and p38β, and p38γ and p38δ,
respectively [22,23]. In addition, there are other atypical MAPKs that have unique regulation and
function including ERK3/4, ERK7/8, and Nemo-like kinase (NLK) [20,21,24,25].
Growth factor-initiated signaling is associated with the ERK pathway, whereas the JNK and p38
pathways are activated by cytokines, growth factors, environmental stress, and other stimuli (Figure 1).
In the p38 pathway, MKK3/6 acts as mitogen-activated protein kinase kinases (MAP2Ks) and is activated
by mitogen-activated protein kinase kinase kinases (MAP3Ks) such as apoptosis signal-regulating kinase 1
(ASK1), transforming growth factor-β-activated kinase 1 (TAK1), mitogen-activated protein kinase kinase
kinase 1 (MEKK1), and mitogen-activated protein kinase kinase kinase 11 (MLK3). These MAP3Ks also
play a role in the JNK pathway, where they target MAP2Ks such as MAP kinase 4 (MKK4)/MAP kinase
7 (MKK7), which activate JNK1/2. In the ERK signaling pathway, ERK1/2 is activated by MEK1/2 and
activated by RAF, which is activated by RAS, and RAS is related to the plasma membrane by activation of
receptor tyrosine kinases (RTKs), epidermal growth factor receptor (EGFR), vascular endothelial growth
factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR) [20,26].
2.1. JNK/MAPKs
In normal liver, the JNK family is minimally or transiently activated, the latter usually physiological,
whereas sustained activation is pathological. In addition to their central role in hepatic physiological
responses (such as cell death, apoptosis, and cell cycle regulation) [27,28], JNK plays a carcinogenic role
by promoting inflammation, proliferation, invasion, and angiogenesis, depending on the specific context
and duration of the activation of the JNK signaling pathway [29,30]. Earlier studies have reported that
the JNK signaling pathway plays a significant role in the development of HCC [31,32]. In particular,
Jnk1 seems to be more important in malignant transformation and hepatocellular carcinoma (HCC)
development [33,34]. However, during the progression of liver disease, the deletion of Jnk1 significantly
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exacerbated apoptosis, compensatory proliferation, and carcinogenesis in experimental chronic liver
disease. In turn, Jnk2 was reported to modulate necrosis and inflammation [35]. Using Puma KO
mice in diethylnitrosamine (DEN)-induced HCC, HCC formation was suppressed, a phenomenon
associated with reduced cell death and compensatory proliferation of hepatocytes. However, such
effects were inhibited by the administration of the JNK inhibitor SP600125 [36]. In human HCC cell
lines, Jnk1 activation is associated with tumor size. By knocking down Jnk1 but not Jnk2, proliferation
of human HCC occurs via upregulation of cmyc and downregulation of p21 [37].Cells 2019, 8, x FOR PEER REVIEW 3 of 27 
 
 
Figure 1. MAPK signaling pathway: ERK1/2, JNK1/2, and p38. Activation of ERK begins with the 
phosphorylation of MEK1/2, followed by activation of tyrosine and threonine residues. Activated 
RAF binds to and phosphorylates the kinases MEK1/2 as well as activated RAS. The RAS activation 
occurs at the plasma membrane and is mediated by son of sevenless (SOS), a guanine nucleotide 
exchange factor (GEF). Signals from cell surface receptors are passed through RAS-GTP to the 
RAF(A/B/C) and/or PI3K, the latter then activates the PI3K/AKT signaling pathway. RAF also receives 
signals from the activated ligands’ G protein-coupled receptors (GPCRs). Activated RAF is capable of 
phosphorylating MEK, and subsequently, the ERK/MAPK signaling pathway. After activation of 
ERK, ERK1/2 moves to the cytoplasm and nucleus to phosphorylate other proteins. These proteins 
are responsible for cell regulation, growth, differentiation, and mitosis. JNK is activated in response 
to cytokines, growth factors, pathogens, stress, etc., and is associated with the transformation of 
oncogenes and growth factor pathways. Activation of JNK requires dual phosphorylation tyrosine 
and threonine, the MAP2Ks that catalyze this reaction are known as MKK4 (also known as SEK1) and 
MKK7. MKK4/7 are phosphorylated and activated by MAP3Ks, TAK1, and ASK1. Tumor necrosis 
factor (TNF) receptor signaling and ROS might be the major upstream mediators of JNK activation. 
Abnormal activation of the JNK signaling pathway is linked to the development of cancer, diabetes, 
inflammatory diseases, and neurodegenerative diseases. The activation of p38 is mediated by 
upstream kinases, MAP kinase 3 (MKK3), and MAP kinase 6 (MKK6). MKK3/6 are activated by 
MAP3Ks such as ASK1 and TAK1, which respond to various extracellular stimuli including osmotic 
shock, inflammatory cytokines, lipopolysaccharides (LPS), UV light, and growth factors. 
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Figure 1. MAPK signaling pathway: ERK1/2, JNK1/2, and p38. Activation of ERK begins with the
phosphorylation of MEK1/2, followed by activation of tyrosine and threonine residues. Activated RAF
binds to and phosphorylates the kinases MEK1/2 as well as activated RAS. The RAS activation occurs
at the plasma membrane and is mediated by son of sevenless (SOS), a guanine nucleotid exchange
factor (GEF). Signals from cell surface receptors are passed through RAS-GTP to the RAF(A/B/C) and/or
PI3K, the latter then activates the PI3K/AKT signaling pathway. RAF also receives signals from the
activated ligands’ G protein-coupled receptors (GPCRs). Activated RAF is capable of phosphorylating
MEK, and subsequently, th ERK/MAPK signaling pathway. After activation of ERK, ERK1/2 moves to
the cytoplasm and nucleus to phosp rylate oth r proteins. These proteins re respo sible for cell
regulation, growth, differentiation, and mitosis. JNK is activated in response to cytokines, growth
factors, pathogens, stress, etc., and is associated with the transformation of oncogenes and growth
factor pathways. Activation of JNK requires dual phosphorylation tyrosine and threonine, the MAP2Ks
that catalyze this reacti are known s MKK4 (also known as SEK1) and MKK7. MKK4/7 are
phosphorylated and activated by MAP3Ks, TAK1, and ASK1. Tumor necrosis factor (TNF) receptor
signaling and ROS might be the major upstream mediators of JNK activation. Abnormal activation of
the JNK signaling pathway is linked to the development of cancer, diabetes, inflammatory diseases,
and neurodegenerative diseases. The activation of p38 is mediated by upstream kinases, MAP kinase
3 (MKK3), and MAP kinase 6 (MKK6). MKK3/6 are activated by MAP3Ks such as ASK1 and TAK1,
which respo d to various extracellular stimuli inc uding osmo ic shock, inflammatory cytokines,
lipopolysaccharides (LPS), UV light, and growth factors.
The JNK signaling pathway has been recently implicated in CCA development. JNK plays an
important role in regulating the interaction between different pro-apoptotic and anti-apoptotic proteins
in response to both external and i ternal apoptotic sti uli [38]. In human CCA, high expression
of TNFA in cells near CCA lesions was found and phosphorylation of JNK in cholangiocytes (80% in
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CCA patients) as well as the accumulation of reactive oxygen species (ROS) around the peripheral
hepatocytes occurred. Accumulation of ROS leads to caspase-3-dependent apoptosis via JNK. At the
same time, Yuan et al. [39], showed that mitochondrial dysfunction and oxidative stress promoted
cholangiocellular overgrowth and tumorigenesis. In this study, cholangiocellular proliferation and
oncogenic transformation were promoted through the JNK signaling pathway, which was activated
by Kupffer cells (KC), subsequently leading to liver damage, ROS, and the paracrine release of TNF.
Therefore, KC-derived TNF might promote cholangiocellular cell proliferation, differentiation, and
carcinogenesis, suggesting that the ROS/TNF/JNK axis plays a significant role in the development of
CCA. Another study that tested the antioxidant activity of using guggulsterone, a steroid found in
the resin of the guggul plant (Commiphora wightii) in both HuCC-T1 and RBE CCA cell lines, showed
that guggulsterone could induce the apoptosis of human CCA cells via ROS-mediated activation of
the JNK signaling pathway [40]. Feng et al. [41] reported that JNK exerted its carcinogenic effect in
human CCA cells, partially because the mammalian target of the rapamycin (mTOR) pathway was
regulated by the induction of glucose-regulated protein 78 (GRP78). They showed that eukaryotic
initiation factor-α (eIF2a)/activated transcription factor 4 (ATF4) signaling promoted the accumulation
of GRP78; whilst JNK was both promoted by the activation of mTOR and characterized by a high
expression of GRP78. These results indicated that GRP78 contributed to the pro-tumorigenic function
of JNK in human CCA cells, partly through promoting the eIF2α/ATF4/GRP78 pathway, and through
JNK/mTOR signaling. As above-mentioned, the JNK/MAPKs signaling pathway may be a key target
in the treatment of CCA; however, more studies are needed to test this possibility.
2.2. p38/MAPKs
The p38 kinase plays a key role by promoting proliferation, invasion, inflammation, and
angiogenesis in the occurrence and development of CCA [42–45], also affecting the growth of malignant
human CCA cells, and maintaining the phenotype of transformed cells [45,46]. p38δ can be used for
differential diagnosis of CCA, since it is not expressed in HCC cells [47]. IL-6 receptors and tyrosine
kinases receptors such as Met (c-MET) and the EGFR family members ERBB2 and ERBB1 (EGFR)
are key signaling pathways in CCA. Members of the EGFR family, particularly EGFR and ERBB2
(HER-2/neu), are involved in the pathogenesis of CCA [15,48,49]. Dai et al. [50] reported that both p38
and C-MET, the tyrosine kinase receptor for hepatocyte growth factor (HGF), promote the proliferation
and invasion of human CCA cells, and p38 promotes CCA formation via sustained activation of C-MET.
In addition, using ATO (arsenic trioxide) alone or in combination with metformin to treat CCA cell lines,
Ling et al. [42] found that inactivation of p38 by the inhibitor SB203580 or specific siRNA could enhance
the anticancer efficacy of single drug or combination of metformin and ATO, especially using ATO alone.
Furthermore, the expression of P38δ was upregulated in CCA when compared to normal biliary tissue.
Inhibition of P38δ expression by siRNA transfection significantly reduced CCA cell proliferation and
invasion. Conversely, overexpression of P38δ in CCA cells can induce an increase in tumor invasiveness.
2.3. ERK/MAPKs
Previous studies have reported an upregulation of the RAS-ERK1/2 signaling pathway in CCA [51].
TGF-β transmits signals through SMAD2/3 phosphorylation, but can also transduce signals via
RAS-ERK1/2, PI3K, p38, and Rho pathways [52–54]. Rac1, a member of the Rho family of small
GTPases, plays a pivotal role in the development of CCA [55,56]. Li et al. [57] demonstrated that integrin
β6 promoted tumor cell malignant behavior by activating Rac1. In biliary dysplasia, hyperplasia and
CCA, TGF-β is overexpressed, a mechanism associated with CCA initiation and formation [51,58,59].
Moreover, ERK1/2 activation has also been linked with TGF-β-induced epithelial to mesenchymal
transition (EMT) and cell invasiveness. One study using CCA cell lines indicated that TGF-β enhanced
cell invasiveness and mesenchymal features in CCA cell lines [58]. Recently, a study using CCA cell lines
(KKU-M213 and HuCCA-1) showed that TGF-β activates ERK1/2 via the SMAD2/3 pathway, enhancing
TGF-β activity to promote tumor growth [60]. As above-mentioned, TGF-β can also transduce signals
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via the RAS-ERK/PI3K pathways [52–54]. The PI3K/AKT/PTEN signaling pathway is significantly
overexpressed in human CCA tissue [61], therefore it is another important pathway involved in the
development of CCA associated with RAS/ERK/MAPKs. PI3K is one of the most important factors
in RAS activation and can be involved in the regulation of various functions including cell growth,
cell cycle entry, cell survival, cytoskeleton reorganization, and apoptosis [15,62,63] (Figure 1). Loss of
phosphatase function of PTEN will result in the constitutive activation of (PI3K/protein kinase B) AKT
signaling pathway in CCA. Inhibition of PI3K/AKT signaling effectively blocked the proliferation and
invasive behavior of CCA [61]. At the same time, Hyunho et al. [64] using CCA cell lines (SCK and
Choi-CK) with inactivation of AKT, showed decreased expression of BCL2, and enhanced expression
of BAX, thereby inducing the apoptosis of resistant cells; whilst the inhibition of ERK1/2 activation did
not induce apoptosis, but decreased tumor cell growth. These results indicated that the AKT/ERK1/2
signaling transduction pathway might mediate apoptosis in CCA cell lines. Furthermore, in CCA,
the expression of the HGF receptor (HGFR) encoded by the MET gene, also known as cMET, is increased
(12–58%). Activation of MET promotes cell invasion and triggers metastasis by directly participating
in tumor angiogenesis [65]. Experiments with CCA cell lines indicate that HGFR-dependent CCA cell
invasiveness occurs via the AKT/ERK signaling pathway [66–68]. In summary, abundant evidence
suggests that the ERK signaling pathway is intimately related to cholangiocarcinogenesis. In the future,
the ERK signaling pathway may be an effective target for the diagnosis and treatment of CCA; however,
more research is needed to confirm this.
2.4. ‘Other’ Kinases
Kinases such as transforming growth factor-β-activated kinase 1 (TAK1) belong to the MAP3Ks
family. TAK1 is activated in response to cytokines such as TNF, LPS, and TGF-β in multiple
cellular systems [69]. Activation of the TGF-β receptor triggers downstream signaling mediated by
SMAD family of proteins, which promotes EMT progression in CCA (discussed below). However,
phosphorylated TAK1 activates IKK (IκB kinase) and MKK4/7, causing the activation of NF-κB
and JNK. Deletion of TAK1 in liver parenchymal cells (both hepatocytes and cholangiocytes)
promotes hepatocyte death, inflammation, fibrosis, and hepatocarcinogenesis, coinciding with biliary
ductopenia and cholestasis [70–72]. ASK1 is another member of the MAPK family, known as MAP3K5
(mitogen-activated protein kinase kinase kinase 5), which can activate the P38 and JNK pathways
in response to both oxidative and ER (endoplasmic reticulum) stress as well as stress-induced via
inflammatory cytokines (such as TNFα) [73–75].
3. EMT Transition
Previously, it was generally believed that HCC originated from hepatocytes and that CCA
originates from bile duct cells [62]. Moreover, biliary epithelial cells (BECs) may be involved in liver
fibrosis [76]. During acute and chronic cholestasis, liver fibrosis involving an increasing number of
ductules (the finest ramifications of the biliary tree), is accompanied by polymorphonuclear leukocyte
infiltration and increased extracellular matrix deposition, leading to periportal fibrosis and finally
PBC (primary biliary cholangitis) [77]. Diaz et al. [78] presented histological data suggesting that
EMT occurs in human liver fibrosis, particularly in diseases associated with prominent bile ductular
proliferation including biliary atresia and PBC. Other studies indicated that proliferating cholangiocytes
play a key role in the induction of fibrosis via EMT [76,79,80]. In CCA, developmental changes seen
in cholangiocytes may be due to the activation of hepatic stem/progenitor cells, the proliferation of
bile duct cells, or through ductal metaplasia of mature hepatocytes [81,82]. However, alongside the
progress seen in histopathological studies, there is now a better understanding of the origins of BECs.
Both hepatic progenitor cells (HPCs) [83] and CCA stem cells [62] seem to be capable of differentiating
into BECs (Figure 2), whilst CCA stem cells can also originate from HPCs [62,84,85]. Micrographs of
in vivo fate-tracking experiments showed the contribution of hepatocytes and HPCs to bile duct repair
or hepatocyte injury. In order to cope with biliary tract injury, signals derived from myofibroblasts
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mediate the activation and proliferation of the HPCs niche. This process can be triggered by NOTCH
signal transduction, via JAG1, a NOTCH ligand provided by the stroma of the portal vein, which
induces the differentiation of hepatocytes into BECs [86–88]. These results indicate that CCA can be
derived from common HPCs, which can differentiate into both hepatocytes and cholangiocytes [89,90].
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Figure 2. The hierarchy of cholangiocarcinoma ste cells. Hepatic stem cells grow and differentiate
into hepatic progenitor cells and mature hepatocytes (hepatocytes and cholangiocytes). CCA stem cells
are produced by genetic abnormaliti s of hepati stem cells, hepatic progenitor cells, or CCA cells,
which then grow and differentiate to CCA cells. The NOTCH signaling pathway might induce mature
hepatocytes to develop into CCA (in mice). Cholangiocytes can also transform into CCA cells through
ROS and inflammation-indu ed genetic and epigenetic variation.
In addition, chronic infl mmatory pr c sses can induce the producti n of a variety of cytokines
including TNF, IL-6, TGF-β, and PDGF, promoting the development of CCA by affecting BEC function
and proliferation [18,19]. In other words, EMT may also play an important role in CCA progression.
In 1968, Hay [91] noted that during chick embryo development, epithelial cells underwent
through several differentiation and dedifferentiation stages and migrated a considerable distance in
the body. All of these processes require an interconversion between the epithelial and mesenchymal
cell phenotypes (including ‘multipotent’, mesenchymal stem cells) called EMT, and the opposite
process, mesenchymal–epithelial transformation (MET). EMT is a special physiological process in
which epithelial cells lose polarity and exhibit a physiological process of mesenchymal phenotype.
Subsequently, as research progresses, multiple in vivo studies have also been reported. EMT is critical
for embryonic development, wound healing, stem cell biology, and plays a key role in the tumorigenic
process [92,93]. The first change occurs when epithelial cells lose cell–cell adhesions (at specialized
adherent junctions) with the disruption of two major components E-cadherin and β-catenin. Tight
junction fractures also occur and result in the loss of apical-basal polarity including cell-extracellular
matrix (ECM) contacts. EMT is now known to be mediated by the so-called EMT-activated transcription
factors (EMT-ATFs) including SNAIL, TWIST, and ZEB families [92]. EMT-ATFs are key mediators of
cell plasticity, playing an important role in all stages of cancer progression from initiation, primary tumor
growth, invasion, dissemination, and metastasis to colonization including resistance to therapy [92,94].
The process from primary tumor to metastasis is very complex, and cancer cells need to adapt to
multiple and changing environments, which are usually harsh. This plasticity of tumor cells is
reflected by the so called back-and-forth transition from differentiation to undifferentiation or partial
EMT-associated cancer cell phenotypes, which promote the formation of tumor cells and facilitate
Cells 2019, 8, 1172 7 of 27
their metastasis [95]. In line with CCA development, at the biochemical level, various morphogenetic
and environmental signals including TGF-β, WNT, EGFR, and PDGF, inflammatory cytokines and
integrin receptor ligands promote EMT [96,97] (Figure 3). Furthermore, TGF-β is also involved in
several steps of cancer from tumorigenesis to metastasis, which promotes cancer cell invasion and
metastasis through an EMT process, although at later stages [98–102].
The canonical TGF-β pathway relies on the downstream SMAD family [103], which are subsequently
phosphorylated after receiving signals from membrane receptors (e.g., EGFR, TNFR, and ILR). The two
phosphorylated R-SMADs are then brought together, recruiting SMAD (co-SMAD) and SMAD4 to form a
trimer that can be transported from the cytosol to the nucleus [104]. In the nucleus, the heterotrimeric
complex binds to DNA in a sequence-specific manner alone or in combination with other coactivators
to trigger the transcription of target genes such as SNAIL1, SNAIL2, and other oncogenes [105,106].
The formation of protein complexes between phosphorylated R-SMADs and SMAD4 is a central event
in the TGF-β signaling pathway including apoptosis, cell growth and differentiation, and extracellular
matrix production [107,108]. Activation of the TGF-β-induced SMADs independent pathway (i.e.,
the non-canonical pathway) is achieved via TAK1 and JNK/P38 signaling. Interestingly, JNK induced
phosphorylation of R-SMAD can activate the EMT programming process. Both JNK and p38 can synergize
with SMADs to promote non-canonical TGF-β-induced apoptosis [96,109–111]. In SMAD-independent
pathways TGF-β can also induce AKT phosphorylation and rapidly activate PI3K, which is possibly
involved in SMAD2-induced EMT [112]. Studies on keratinocytes indicate that the PI3K/AKT pathway
contributes to completion of TGF-β-induced SMADs-dependent EMT. Similarly, the TGF-β-induced
ERK/MAPKs pathway contributes to EMT induction, as ERK is required to remove cell adhesion junctions,
which leads to increased cell migration [96,110,113] (Figure 3).Cells 2019, 8, x FOR PEER REVIEW 8 of 27 
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platelet-derived growth factor D (PDGF-D), promoting CCA cell migration through PDGFR-β, RHO-
Figure 3. Schematic diagram of the EMT and MET progress in the CCA program. Healthy epithelial
cells have a tight junction between the apical-basal polarity and interaction with the basement
membrane. T se cells express markers of pithelial cell lines such as the adhesive connexin
E-cadherin. After stimulation, epithelial cells undergo EMT progression (EMT-induced EMT-TFs
results in downregulation), lose cell to cell and cell–ECM connections, lose epithelial markers, express
interstitial markers (N-CADHERIN, β-CATENIN), obtain front–back polarity, and enhance migration.
During tissue rep ir or inflammation regression, MET is initiate , and the c lls rea quire their epithelial
phenotype. Cytokines (TGF-β, TNF-α, and IL-6), tyrosine kinase receptors (EGF, HB-EGF), and their
receptors (TGFβR, EGFR, TNFR, and ILR) involved in developmental processes play a key role in
the induction of the EMT program by activating intracellular signaling pathways (including MAPKs,
IL-6/STAT3, NOTCH/JAG1, and WNT), involved in CCA progression and metastasis.
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4. Tumor-Associated Macrophages (TAMs) and Cancer Associated Fibroblasts (CAFs)
Macrophages and fibroblasts are the main components of infiltrating stromal cells, called
tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), respectively. CAFs
are a heterogeneous cell population; every tumor type consists of tumor- and tissue-specific CAF
subpopulations [114–116]. Different markers have been used to identify these subgroups including
α-smooth muscle actin (α-SMA), fibroblast-specific protein 1 (FSP1), fibroblast activation protein (FAP),
and neuron glial antigen-2 (NG2) [116,117]. In human CCA, hepatic stellate cells (HSCs) are thought
to be the dominant cellular source of CAFs [118], whilst other studies suggest that CCA-associated
CAFs might be derived from portal fibroblasts (PFs) and from bone marrow derived fibrocytes
(BMDFs) [119–121]. Activation of CAFs is associated with an invasive phenotype of the tumor in
CCA [122]. TAMs and CAFs have also been reported to be involved in tumor progression [56,123,124]
as well as in the RAS, MAPK, and MET signaling cascades. On the other hand, TAMs can promote
the secretion of tumor growth-promoting factors such as TNF-α, IL6, TGF-β, PDGFR, and VEGFR,
among others. These factors can usually act on EMT, promoting tumor growth, and metastasis in
CCA [56,125–127]. Cadamuro et al. [56] suggest that CCA cells recruit CAFs by secreting platelet-derived
growth factor D (PDGF-D), promoting CCA cell migration through PDGFR-β, RHO-GTPase, and
JNK activation. The recruitment of macrophages is often supported by CAFs and epithelial tumor
cells, and is also stimulated by regulatory signaling pathways (e.g., NOTCH and IL6/STAT3) [128–130].
In addition, neutrophil migration can be induced by the P13K/AKT and MAPKs signaling pathways,
which are manifested by the recruitment of neutrophils in CCA [131]. According to recent studies,
CAFs are able to promote CCA progression through interacting autocrine and paracrine signaling
pathways, especially in promoting EMT [97,132].
As above-mentioned, the NOTCH signaling pathway (including the NOTCH ligand JAG1) seems
to be another particularly important reason for CCA formation. In a murine model of liver cancer
driven by transfection of activated forms of AKT and RAS oncogenes, inhibiting NOTCH and its ligand
JAG1 markedly impairs CCA development. According to cell-fate tracing experiments, combined
activation of NOTCH and AKT could induce mature hepatocytes to develop into CCA in mice [133,134]
(Figure 2). Moreover, a recent study from Thongsom’s group [135] demonstrated that piperlongumine
(PL), a naturally-occurring small molecule, could induce CCA cellular apoptosis through ROS-mediated
JNK/ERK activation and proteasome inhibition, while the susceptibility of CCA to PL therapy may
depend on the activation of AKT. In fact, overwhelming evidence indicates that it is possible to convert
hepatocytes into CCA cells when exposed to specific stimuli, and that the key driving factor in this
process is NOTCH signal transduction [133,134]. Indeed, activation of the NOTCH signaling pathway
induces EMT and increases CCA cell line migration [136–138].
Several reports have linked the p38 signaling pathway to the regulation of EMT [139–142]. As noted
previously, there is crosstalk between the p38 and the JNK signaling pathways. The JNK and p38 MAPKs
pathways share several upstream regulatory factors, so multiple stimuli may activate both pathways.
As previously shown, p38 responds to ROS accumulation to prevent tumorigenesis by promoting
growth stagnation and apoptosis [143,144]. ROS can promote TNF-α to activate the JNK signaling
pathway and lead to apoptosis. However, TNF-α can also activate NF-κB to inhibit ROS through related
genes such as MnSOD (manganese-superoxide dismutase) and FHC (ferritin heavy chain), thereby
preventing JNK activation and inhibiting apoptosis [145,146]. While activation of p38 promotes MSK1/2
(mitogen- and stress-activated protein kinase 1/2), and subsequently, NF-κB [147,148]. Furthermore,
the JNK signaling pathway has been shown to regulate tricellulin-mediated tight junctions in human
pancreatic ductal epithelial cells, indicating that it may play an important role in the differentiation of
ductular cells [149,150].
As demonstrated in previous studies, TNF-α may alter the differentiation of hepatocytes in liver
disease [151]. In TNF-α-stimulated fibroblast death, JNK activation plays a dual role, inhibiting
not only TNF-α-stimulated apoptosis, but also TNF-α-induced necrosis [152,153]. Earlier studies by
Nishikawa’s group [151] demonstrated that, within the collagen-rich matrix, TNF specifically stimulated
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branching morphogenesis associated with the expression of bile duct/ductular markers including
cytokeratin 19 (CK-19). Meanwhile, the phosphorylation of JNK and c-Jun increased during collagen
gel culture, and TNF-α strongly enhanced bile duct transdifferentiation of hepatocytes, principally by
inhibiting hepatocyte differentiation and enhancing ductular morphogenesis. Interestingly, in human
liver-fluke-associated CCA, overexpression of TNF-α and NF-κB are characteristic [154].
Several studies have shown that CAFs from human CCA are capable of synthesizing HB-EGF
(heparin binding EGF like growth factor) with the activation of EGFR in CCA cells, promoting disruption
of cell–cell junctions and increased invasiveness [97,155,156]. EGFR expression and signaling are
closely related to the development and progression of CCA [17,157]. Abnormal phosphorylation
of EGFR family receptors activates p38, increases COX-2, inhibits apoptosis, and promotes tumor
growth [158,159]. Simultaneously, epigenetic regulation of IL-6 promotes the progression of CCA
by affecting promoter methylation and gene expression in growth regulatory pathways including
EGFR [160]. Another study using sulfated galactans (SG) isolated from the red seaweed Gracilaria
fisheri inhibited CCA cell proliferation by inhibiting EGFR and ERK phosphorylation, and blocking
EGF-induced cell proliferation. These results suggest that SG may interact with EGFR and mediate
cell proliferation inhibition, partly by blocking the endogenous activation of the EGFR/ERK/MAPKs
signaling pathway [161].
5. Biomarkers and Diagnosis
The development of CCA involves genetic alterations of related oncogenes in
humans [12,130,162–167] (Table 1). Mutations common to tumors all along the chromosome include
tumor suppressor genes (TP53, and PTEN), chromatin-remodeling genes (ARID1A, ARID1B, BAP1,
PBRM1), and gain of function of oncogenes (KRAS, BRAF, and PIK3CA). However, mutations in the
ERK/MAPKs pathway components are relatively common in CCA. In particular, KRAS mutations are
associated with a decrease in both progression-free, and overall survival in CCA patients [168]. KRAS
activating mutations are frequently detected (22%, range 5–57%) [17,169,170], especially in codon
12 hotspots, and have recently been identified as an independent predictor of poor survival after
surgery [170,171].
Table 1. Genetic alterations of related oncogenes in human CCA.
Oncogenes Tumor Suppressor Genes Chromatin-Remodeling Genes Gain of Function of Oncogenes
MLL3 TP53 ARID1A KRAS
ROBO2 PTEN ARID1B BRAF
RNF43 BAP1 PIK3CA
PEG3 PBRM1
GNAS
NRAS
PTPN3
CDKN2A
SMAD4
IDH1/2
Oncogenes in humans CCA include KMT2C (lysine methyltransferase 2C), roundabout guidance
receptor 2 (ROBO2), ring finger protein 43 (RNF43), paternally expressed 3 (PEG3), guanine nucleotide
binding protein (G protein) alpha stimulating activity polypeptide 1 (GNAS), (BRCA-associated
protein 1 (BAP1), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS
viral (v-ras) oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF),
polybromo 1 (PBRM1), AT rich interactive domain 1A (SWI-like) (ARID1A), AT-rich interaction domain
1B (ARID1B); phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA), phosphatase and
tensin homolog deleted on chromosome ten (PTEN), protein tyrosine phosphatase non-receptor type
3 (PTPN3), cyclin dependent kinase 2a/p16 (CDKN2A), mothers against decapentaplegic homolog 4
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(Drosophila) (SMAD4), tumor protein p53 (TP53), isocitrate dehydrogenase 1 (IDH1), and isocitrate
dehydrogenase 2 (IDH2).
As previously mentioned, carcinogenesis in CCA is characterized by recruitment of fibroblasts,
ECM remodeling, changes in immune cell migration patterns, and promotion of angiogenesis [172].
Matrix metalloproteinases that degrade and remodel the ECM including MMP1, MMP2, MMP3, and
MMP9 are strongly expressed in CCA and are associated with invasive tumors. CCA does not always
exhibit a tubular contour, which is easily recognized in histopathological studies; instead, cancer cells
often appear nodular or exhibit a form of HCC resembling a neuroendocrine or mixed solid shape [173].
CCA cells usually grow along the wall of the portal vein in connective tissue and directly intrude into
the nearby bile ducts.
In practice, immunohistochemical detection of CK-7, CK-19, CK-20, CDX-2, and CA199 biomarkers
is often used to identify CCA [12,174]; whilst CK-7 and CAM5.2 biomarkers are strongly expressed in
CCA cells. Immunohistochemical detection of human EpCAM on the cell membrane is positive in
90% of cases, while the presence of CK-19 is found in approximately 70% to 80% of cases [164,175,176].
In addition, within the NOTCH signaling pathway, SOX9 plays an important role in the pathophysiology
of the biliary tract, and SOX9 has been shown to be associated with the progression of EMT in
CCA [177,178]. Unfortunately, none of these immunophenotypes are entirely specific for CCA, since
they are often also seen in pancreatic ducts and bile duct primordial cells. Accurate diagnosis of CCA
depends mainly on clinical symptoms, histopathology, and imaging findings [173]. Even though
recent studies have found that modified branched-chain DNA probes for albumin mRNA (used for
in situ detection of albumin expression) have a detection rate of 99% for CCA and 100% for liver
cancer [179], these are not detected exclusively in CCA, not even in early stages. As such, most patients
are diagnosed with CCA at advanced stages and have limited treatment options, resulting in a poor
prognosis [180].
The combination of clinical and biochemical findings including abdominal pain/distension,
pruritus, jaundice, and weight loss, imaging techniques like ultrasound (US), computed tomography
(CT), magnetic resonance imaging (MRI), 18F-fluorodeoxyglucose positron emission tomography
(18FDG-PET), and serum analysis of non-specific tumor biomarkers such as CA199, CEA
(carcinoembryonic antigen), and CD133 [180], usually help to diagnose CCA, but ultimately liver
biopsy and pathological diagnosis are used as the gold standard [181].
6. Therapy
6.1. Surgical Treatment
Currently, surgical resection is still the preferred treatment for CCA. However, only a small
number of patients (about 35%) are diagnosed sufficiently early to undergo surgery [182]. In 2012,
the 5-year survival rates of surgically treated CCA, iCCA, pCCA, and dCCA were 22–44%, 11–41%, and
27–37%, respectively [4]. However, a recent study including 574 patients with pCCA that underwent
right hepatic artery resection and reconstruction, with a perioperative mortality rate of less than 5%,
showed a 5-year survival rate of 30% [183]. Contraindications to CCA surgical resection include
bilateral, multifocal disease, distant metastases, and comorbidities associated with surgical risk that
exceed the patient’s expected surgical benefits. Regional lymph node metastasis is not considered an
absolute contraindication to resection, although N1 disease (CCA with regional lymph node metastases
including nodes along the cystic duct, common bile duct, hepatic artery, and portal vein) is one of the
prognostic factors representing poor prognosis [184–186]. Although Bismuth-Corlette type IV pCCA is
not considered to be an absolute contraindication to surgical resection, subsequent orthotopic liver
transplantation (OLT) is a valid treatment after neoadjuvant radiotherapy [187]. The recurrence rate
was 20% and the 5-year survival rate was 68% [187]. However, the selection criteria were strict and
25% to 31% of patients developed disease progression while waiting for OLT and were excluded from
the protocol [186,187]. Therefore, single-OLT is not recommended as a CCA monotherapy because of
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high recurrence rates and long-term survival rates of less than 20% [5,188]. Current guidelines for CCA
are still controversial, but due to regional differences between Eastern and Western centers, different
surgical resection criteria and surgical strategies are based on applied areas, especially between the
Western (US and Europe) and the Eastern centers, with aggressive surgical procedures (including
extended hepatectomy and combination with vascular resection in early pCCA). Thus, the actual
resection rate of CCA patients has increased, and the prognosis improved in East Asia [183,189,190].
6.2. Non-Surgical Treatment: Targeted Therapies
The complexity of the pathogenesis and the apparent heterogeneity of CCA have hindered use of
efficacious clinical therapeutics in their management [39,191,192]. The combination of gemcitabine
and cisplatin (Table 2) is the first-line chemotherapy for patients with advanced CCA (not suitable for
local treatment and surgery) and is also suitable for various anatomical disease subtypes. The median
survival of the combination was 11.7 months, and 8.1 months with gemcitabine alone [193,194].
Activation of EGFR leads to downstream activation of MAPKs, however, the efficiency of the EGFR
inhibitor erlotinib in clinical trials of CCA is limited according to a Multicenter Phase II clinical trial
testing [165,195]. A recent phase III randomized controlled trial showed that by combining erlotinib
with gemcitabine/cisplatin, patients had a higher response rate (31% vs. 14%, p = 0.004) and longer
survival (5.9 months vs. 3.0 months, p = 0.049) [196].
Locoregional treatments including radiofrequency ablation, transcatheter arterial
chemoembolization (TACE), drug eluting beads-TACE, selective 90Y internal artery radiotherapy,
and microsphere or external radiation therapy are also applied in CCA [186]. Since technology and
equipment have improved, the safety and efficacy of radiotherapy for CCA are better. Advances in
these techniques and devices can also increase the radiation therapy dose of biliary tumors and/or
improve the protection of non-malignant tissues, thereby improving the therapeutic benefit of radiation
therapy for CCA [197–200].
Molecularly Targeted Therapy
Recently, there are several new methods available for CCA including molecularly targeted therapy
and immunotherapy. The FGFR inhibitor NVP-BGJ398 exhibits the potential to treat CCA [201,202].
Some clinical studies are currently testing patients with advanced CCA who have FGFR changes
(NCT02150967), (NCT01703481), (NCT02699606), and (NCT02265341) [12,203,204]. BGJ398 and another
small molecule, FGFR inhibitor PD173072, inhibit the downstream carcinogenic activity of MAPK
signaling and FGFR fusion kinase. The clinical efficacy of BGJ398 is currently under assessment
in a phase I clinical study for advanced solid tumors, with FGFR1/FGFR2 amplification or FGFR3
mutation (NCT01004224) [165,202,205]. ALK (EML4(echinoderm microtubule-associated protein-like
4)–ALK(anaplastic lymphoma kinase)) and the ROS1 inhibitor Ceritinib are currently being evaluated
in a phase II clinical trial of patients with ROS1-positive or ALK-positive advanced-stage pCCA or iCCA
(NCT02374489), (NCT02638909), and (NCT02568267) [12]. Anti-MEK therapies in CCA have been
tested [206–210]. Binimetinib (MEK162), a potent, selective oral MEK1/2 inhibitor, showed promising
evidence of activity in patients with biliary tract cancer [207]. PD901, a MEK inhibitor, has been shown
to be effective against CCA harboring KRAS oncogenic mutations via inhibition of cell proliferation
and modulation of the tumor microenvironment [208]. Cabozantinib is a multi-kinase inhibitor with
anti-MET and anti-VEGFR2 activity. Unfortunately, its activity is limited, median progression-free
survival (PFS) is 1.8 months, and has significant toxicity to unselected patients with CCA [209]. Similarly,
trametinib, in combination with pazopanib, an oral VEGFR tyrosine kinase inhibitor, in patients with
advanced CCA, did not achieve a statistically significant improvement in 4-month PFS over the
prespecified null hypothesized 4-month PFS [210]. Sorafenib, a multi-kinase inhibitor with anti-VEGFR
and RAF family kinase activity (inhibitor of the RAF/MEK/ERK pathway) [211], combined with the
EGFR inhibitor Erlotinib in the treatment of advanced CCA, has been disappointing [212]. Due to
chemoresistance, gene therapy capable of selectively inducing human organic cation transporter type 1
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(hOCT1) in tumor cells was suggested as a potentially useful chemosensitization strategy to improve the
response of CCA to sorafenib [213,214]. Again, it has been reported that hot-spot mutations in the IDH1
and IDH2 genes are frequent in CCA and can promote epigenetic alterations through the regulation of
DNA demethylases activity [215]. Small molecules that inhibit the neomorphic activity of mutant IDH
can reverse DNA methylation, and, in fact, may promote cancer cell differentiation. Such inhibitors may
however also be candidates for the treatment of CCA [216–219]. Therefore, small molecule inhibitors
of mutant IDH1 or IDH2 have demonstrated efficacy, and, in fact, orally available compounds such as
AG-120 have entered clinical trials (inhibitor of mutant IDH1) [220]. Preliminary studies treating CCA
patients with mutated IDH1 with AG-120 in Phase I clinical trials (dose escalation and dose amplification
cohort studies) showed that this inhibitor was safe and effective (NCT02073994) [221]. Enasidenib, a
selective inhibitor of mutant IDH2, is currently being studied in multi-phase I/II trials in patients with
IDH2-mutant advanced-stage solid tumors including CCA(NCT02273739) [12]. Anetumab ravtansine,
an anti-mesothelin antibody-drug conjugate, is undergoing Phase I trials to recruit patients with
advanced-stage CCA with abnormal expression of mesothelin [12]. CDKN2A is a gene encoding
the tumor suppressor proteins p16INK4A and p14ARF and is an important negative regulator of cell
cycle progression. Repetitive focal loss of cdkna2 highlights the potential of CDK4/6 inhibitors in the
treatment of CCA including ribociclib and palbociclib [16,166,222]. Several studies have found a subset
of CCA patients with high expression of PD-1/PD-L1, suggesting that these patients may be suitable
for treatment with PD-1 or PD-L1 inhibitors (NCT02703714, NCT02628067) [223–225] (Table 1).
Table 2. Targeted therapies against cholangiocarcinoma.
DRUG Target Phase Identifier
AG-120 [226] IDH1 I NCT02073994
Enasidenib [12] IDH2 I/II NCT02273739
JNJ-42756493 [227] FGFR I NCT01703481
BGJ398+ PD173072 [165,202,205] FGFR I NCT01004224
NVP-BGJ398 [201,202] FGFR II NCT02150967
Ponatinib [228] FGFR II NCT02265341
Ceritinib [229] ROS1-ALK II NCT02638909
LDK378 (Ceritinib) [229] ROS2-ALK II NCT02374489
Entrectinib [230] ROS3-ALK II NCT02568267
Binimetinib (MEK162) [207] MEK1/2 I NCT00959127
Trametinib and Pazopanib [210] MEK/VEGFR II NCT01438554
Cabozantinib [209] c-MET-VEGFR2 II NCT01954745
Cisplatin + gemcitabine [193] EGFR III NCT00262769
Gemcitabine/Oxaliplatin + Erlotinib [196] EGFR III NCT01149122
Sorafenib [212] VEGFR-PDGFR-BRAF II NCT00238212
Anetumab ravtansine [12] anti-mesothelin antibody-drug conjugate I NCT03102320
Palbociclib [231] CDK4/6 Inhibitor I/II NCT03065062
Pembrolizumab + GM-CSF [224] PD1 II NCT02703714
Pembrolizumab [232] PD1 II NCT02628067
Inhibitors of the JNK signaling pathway may also play an important role in therapy against
CCA. To date, a number of small molecule inhibitors have been developed that may regulate specific
JNK signaling pathways [31]. One study using the RBE human CCA cell line treated with SP600125,
an inhibitor of JNK, demonstrated enhanced TGF-β-induced cell apoptosis in a SMAD4-dependent
manner, suggesting that JNK inhibition may be an ideal therapeutic candidate for the treatment of
human CCA [233]. However, as JNKs play a pivotal role in normal biological functions, the direct
inhibition of JNK itself may also have unexpected side effects. Therefore, the development of highly
selective JNK1 or JNK2 inhibitors is essential for the safe treatment of cancer [234]. In this regard, it is
important to note that selective inhibition between the individual and their associated JNK proteins
may be involved in normal cell functions (such as adaptive immunity and brain development), and thus
may lead to adverse cellular effects and unwanted toxicity [235–238]. Unfortunately, MAPKs-directed
therapy is not showing the same clinical efficacy as the experimental models. Thus, further research
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should also focus on developing substrate specific inhibitors that can make important contributions to
mitigate different types of cancer [24] including CCA.
7. Conclusions
Recent advances have led to a more profound understanding of the role of the MAPKs
signaling pathway in liver neoplastic diseases. Clinical symptoms, histopathology, and gathering
of detailed molecular information are of great significance for the diagnosis and treatment of CCA.
Utilizing improved experimental models, the important roles of the MAPKs signaling pathway in the
pathogenesis of CCA are emerging. Although the exact potential risk factors for CCA have not yet been
accurately identified, perhaps the mutation profiles identified are closely related to the underlying
causes of CCA. Moreover, some of these mutated proteins can become therapeutic targets for the
treatment of CCA. Exciting new research is revealing that liver cancer progression can be attenuated
by inhibiting or blocking dysregulated cell transduction components of the MAPKs signaling pathway.
If we can elucidate the signal transduction pattern of liver cancer development and carry out specific
blockade in certain aspects, it will herald significant breakthroughs and progress in the diagnosis and
treatment of CCA.
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Abbreviations (in Alphabetical Order)
ALK anaplastic lymphoma kinase
ARID1A AT rich interactive domain 1A (SWI-like)
ASK1 apoptosis signal-regulating kinase 1
ATF4 activated transcription factor 4
ATO arsenic trioxide
BAP1 BRCA-associated protein 1
BECs biliary epithelial cells
BMDFs bone marrow derived fibrocytes
BRAF v-raf murine sarcoma viral oncogene homolog B1;
CA199 carbohydrate antigen 19-9
CAFs cancer-associated fibroblasts
CCA cholangiocarcinoma
CDKN2A cyclin dependent kinase 2a/p16
CDX2 caudal type homeobox 2
CEA carcinoembryonic antigen
c-Met tyrosine-protein kinase Met
CK-7 cytokeratin 7
CK-19 cytokeratin 19
CK-20 cytokeratin 20
CT computed tomography
dCCA distal cholangiocarcinoma
ECM extracellular matrix
EGF epidermal growth factor
EGFR epidermal growth factor receptor
eIF2a eukaryotic initiation factor-α
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EML4 echinoderm microtubule-associated protein-like 4
EMT epithelial to mesenchymal transition
EMT-ATFs EMT-activated transcription factors
ERK extracellular signal-regulated kinase
ERS endoplasmic reticulum stress
FAP Fibroblast activation protein
18FDG-PET 18F-fluorodeoxyglucose positron emission tomography
FHC ferritin heavy chain
FSP1 fibroblast-specific protein 1
GEF guanine nucleotide exchange factor
GNAS guanine nucleotide binding protein (G protein) alpha stimulating activity polypeptide 1
GPCRs G protein-coupled receptors
GRP78 glucose-regulated protein 78
HB-EGF heparin binding EGF like growth factor
HCC hepatocellular carcinoma
HNF hepatocyte nuclear factor
hOCT1 human organic cation transporter type 1
HPCs hepatic progenitor cells
HSCs hepatic stellate cells
iCCA intrahepatic cholangiocarcinoma
IDH1 isocitrate dehydrogenase 1
IDH2 isocitrate dehydrogenase 2
IKK inhibitor of NF-κB kinase
IL6 interleukin 6
ILR interleukin receptor
JNK c-Jun NH2-terminal kinase
KC Kupffer cell
KMT2C lysine methyltransferase 2C
KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
LPC liver parenchymal cells
LPS lipopolysaccharide
MAPKs mitogen-activated protein kinases
MAP2Ks mitogen-activated protein kinase kinases
MAP3Ks mitogen-activated protein kinase kinase kinases
MAP3K5 mitogen-activated protein kinase kinase kinase 5
MEK mitogen-activated protein kinase
MEKK1 mitogen-activated protein kinase kinase kinase 1
MET mesenchymal to epithelial transition
MKK3 MAP kinase 3
MKK4 MAP kinase 4
MKK6 MAP kinase 6
MKK7 MAP kinase 7
MLK3 mitogen-activated protein kinase kinase kinase 11
MMPs Matrix metalloproteinases
MnSOD manganese-superoxide dismutase
MRI magnetic resonance imaging
mTOR mammalian target of rapamycin
NF-κB nuclear factor (NF)-κB
NLK Nemo-like kinase
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog
OLT orthotopic liver transplantation
PBC primary biliary cholangitis
PBRM1 polybromo 1
pCCA perihilar cholangiocarcinoma
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PDGF platelet-derived growth factor
PDGF-D platelet derived growth factor D
PDGFR platelet-derived growth factor receptor
PDGFR-β platelet-derived growth factor receptor-β
PEG3 paternally expressed 3
PTEN phosphatase and tensin homolog deleted on chromosome ten
PFS progression-free survival
PFs portal fibroblasts
PI3K phosphatidylinositol 3-kinase
PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide
PL piperlongumine
PSC primary sclerosing cholangitis
RNF43 ring finger protein 43
ROBO2 roundabout guidance receptor 2
ROS reactive oxygen species
RTKs receptor tyrosine kinases
SG sulfated galactans
SMAD4 sulfated galactans; mothers against decapentaplegic homolog 4 (Drosophila)
SOS son of sevenless
α-SMA α-smooth muscle actin
STAT3 signal transducer and activator of transcription 3
TACE transcatheter arterial chemoembolization
TAK1 transforming growth factor-β-activated kinase 1
TAMs tumor-associated macrophages
TNF tumor necrosis factor
TNF-α tumor necrosis factor alpha
TNFR tumor necrosis factor receptor
TGF-β transforming growth factor-β
TP53 Tumor protein p53
US ultrasound
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
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